The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Share News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,911.00
Bid: 1,910.00
Ask: 1,912.00
Change: 6.00 (0.31%)
Spread: 2.00 (0.105%)
Open: 1,916.00
High: 1,927.00
Low: 1,903.00
Prev. Close: 1,905.00
HIK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Hika Pharma promoted to FTSE 100 but Tullow Oil gets kicked out

Thu, 05th Mar 2015 15:01

Hika Pharmaceuticals and Tullow Oil are switching places at start of the second quarter of this year as the FTSE Group reshuffles components across its leading London benchmarks.In its quarterly review, the FTSE Group have outlined which companies have been promoted or demoted from its indices. The decisions are based on a rise and fall in the company's market capitalisation.Companies with the lowest market cap in the FTSE 100 drop into the FTSE 250 and conversely, companies with the highest market cap on the FTSE 250 get promoted to the FTSE 100.In the case of Hikma and Tullow, the market cap for Hikma at £4.94billion, beats that of Tullow's at £3.24bn. That's helped the pharma company wriggle its way into the leading blue-chip FTSE100 index. Hikma floated on the London Stock Exchange in 2005.Companies that get into the FTSE 100 have an opportunity to see the value of their shares increase as the main London benchmark attracts more demand from fund managers, pension funds and mutual funds who all track the index.When the FTSE100 index was launched, the total market cap of the companies was just over £100bn. As of the September 2014 quarterly review, the total market cap stood at £1.79trn.A drop in Tullow's share price after it reported a £1.3bn pre-tax together with lower oil prices and worries about delays in its West African projects combined to hit the company's market cap. The loss in profit was followed by news of a £1.5bn write-off at the beginning of the year. As such, Tullow will have to make the FTSE 250 its new home.Meanwhile, AA, Imagination Technologies Group and Virgin Money Holdings have all booked a place in the FTSE 250. Virgin Money floated in November 2014, raising £500m and valuing the business at £1.25bn. On Thursday, the company reported that it's doubled its profit to £121.2m.Three companies are heading out of the FTSE 250. They include oil producer Afren, video game retailer Game Digital and Oxford Instruments. Afren's share price has slumped since the announcement that it will default on £9.7m of interest payments that were due on 1 Feb.
More News
3 Jan 2023 09:25

Hikma launches version of Xyrem medicine in US for treating narcolepsy

(Alliance News) - Hikma Pharmaceuticals PLC on Tuesday said it launched an authorised generic version of the Xyrem sodium oxybate prescription medicine in the US for treating narcolepsy.

Read more
3 Jan 2023 09:24

LONDON BROKER RATINGS: Citigroup cuts Wizz Air; Redburn likes CRH

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning, Monday and late Friday:

Read more
3 Jan 2023 09:03

LONDON MARKET OPEN: Stocks jump in first session of 2023

(Alliance News) - Stock prices in London made a strong start to the new year on Tuesday, despite weak Chinese data and the UK suffering a fresh wave of rail strikes.

Read more
3 Jan 2023 07:58

LONDON BRIEFING: Stocks called higher; China factory sector shrinks

(Alliance News) - Stocks in London are expected to start a new year on the front foot on Tuesday, after a mixed session in Asia amid weak Chinese economic data.

Read more
3 Jan 2023 07:46

Hikma launches generic narcolepsy solution in US

(Sharecast News) - Hikma Pharmaceuticals has launched an authorised generic version of Jazz Pharmaceuticals' 'Xyrem 1', or sodium oxybate oral solution, it announced on Tuesday.

Read more
8 Dec 2022 09:48

LONDON BROKER RATINGS: JPMorgan cuts Travis Perkins; BofA likes IAG

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning:

Read more
6 Dec 2022 10:48

RBC Capital Markets starts Hikma at 'outperform'

(Sharecast News) - RBC Capital Markets initiated coverage of Hikma Pharmaceuticals on Tuesday at 'outperform' with a 1,750p price target.

Read more
6 Dec 2022 10:26

LONDON BROKER RATINGS: JPMorgan cuts Lloyds but raises Barclays

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
15 Nov 2022 12:10

Credit Suisse initiates coverage of Hikma at 'outperform'

(Sharecast News) - Credit Suisse has initiated coverage of Hikma Pharmaceuticals with an 'outperform' rating.

Read more
15 Nov 2022 09:58

LONDON BROKER RATINGS: Jefferies cuts Aston Martin to 'underperform'

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
14 Nov 2022 09:25

LONDON BROKER RATINGS: Credit Suisse cuts Ferrexpo to 'neutral'

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
8 Nov 2022 09:39

LONDON BROKER RATINGS: Peel cuts Persimmon; Liberum raises Hammerson

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
3 Nov 2022 11:17

Hikma Pharmaceuticals reiterates 2022 guidance as costs widen

(Alliance News) - Hikma Pharmaceuticals PLC on Thursday reiterated annual guidance for all three of its businesses, continuing to expect them to underperform against 2021 due to rising costs.

Read more
3 Nov 2022 11:08

With tighter purse strings, is parity less probable for the pound?

STOXX 600 down 1.1%

*

Read more
3 Nov 2022 09:28

Banks, insurance dodge carnage as real estate stocks sink

Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at .

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.